Immunotherapy duo shows promise against hard-to-treat colorectal cancer
NCT ID NCT07160647
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This study tests two immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery to people with a specific genetic type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if this approach can eliminate all cancer cells before surgery and to learn more about which patients benefit most. About 29 adults with stage IIB-III rectal cancer that can be surgically removed will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR/MSI-H-TYPE RECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, 310016, China
Conditions
Explore the condition pages connected to this study.